ArticleFrontiers in nutrition2026
Fabrication of silk fibroin peptide-astaxanthin nanocomposites by nanoprecipitation for enhanced stability and antioxidant activity.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Astaxanthin (AST), a potent antioxidant, suffers from poor stability and low solubility, limiting its applications across various fields. To address these issues, this study aims to develop a silk fibroin peptide-astaxanthin (SFP-AST) nanocomposite using a simple nanoprecipitation method. Characterization techniques such as Ultraviolet-visible spectroscopy (UV-vis), fluorescence spectroscopy, circular dichroism (CD), transmission electron microscopy (TEM), dynamic light scattering (DLS) and Fourier Transform Infrared (FTIR) confirmed that SFP stabilizes AST in nanoparticles ranging in size from 150 to 300 nm. Stability testing showed that under alkaline shock conditions, the retention rate of AST in the nanocomposite was 55.6%, whereas the retention rate in the free AST solution was only 43.6%. After 24 h of storage, the retention rate of AST in the nanocomposite was 44.4%, whereas the retention rate in the free AST solution was only 30.8%. Furthermore, 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assays revealed that the SFP-AST nanocomposite exhibited a 62.40% radical scavenging activity, compared to 38.11% for free AST. These results suggest that silk fibroin peptides can effectively stabilize and enhance AST, offering a natural, biocompatible carrier with broad potential applications in functional foods, dietary supplements, and cosmetics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.